Home › Funds › IQ EQ FUND MANAGEMENT (IRELAND) Ltd › RXRX
IQ EQ FUND MANAGEMENT (IRELAND) Ltd position in RXRX
RECURSION PHARMACEUTICALS IN · Health Care
IQ EQ FUND MANAGEMENT (IRELAND) Ltd reported holding 2,678,204 shares of RXRX (RECURSION PHARMACEUTICALS IN) in its Q3 2026 13F filing — a position valued at US$11.1M, representing 0.68% of its reported portfolio and ranking #48 among its reported holdings. IQ EQ FUND MANAGEMENT (IRELAND) Ltd has disclosed RXRX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How IQ EQ FUND MANAGEMENT (IRELAND) Ltd's RXRX position evolved
IQ EQ FUND MANAGEMENT (IRELAND) Ltd first disclosed a stake in RXRX in Q2 2024 at 40,251 shares (US$302K). The position peaked in Q3 2026 at 2,678,204 shares, worth US$11.1M. Across 10 filings, IQ EQ FUND MANAGEMENT (IRELAND) Ltd increased the stake 9 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,678,204 shares valued at US$11.1M — an increase of 73,887 shares quarter over quarter.. Notable position changes include a 105% increase in Q3 2024 (shares rose 3% over the following quarter), a 143% increase in Q4 2024 (shares fell 22% over the following quarter), a 135% increase in Q2 2025 (shares fell 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 40.25K | $301.88K | New |
| Q3 2024 | 82.35K | $542.70K | Add |
| Q4 2024 | 200.47K | $1.36M | Add |
| Q1 2025 | 387.24K | $2.05M | Add |
| Q2 2025 | 911.09K | $4.61M | Add |
| Q3 2025 | 1.77M | $8.66M | Add |
| Q4 2025 | 2.40M | $9.83M | Add |
| Q1 2026 | 2.56M | $7.85M | Add |
| Q2 2026 | 2.60M | $9.56M | Add |
| Q3 2026 | 2.68M | $11.06M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RXRX and 13F data
RXRX (RECURSION PHARMACEUTICALS IN) is a Health Care company. 28 other funds we track also report a position in RXRX — the largest reported positions include ARK Invest (US$184.8M), SOFTBANK GROUP CORP. (US$50.0M), MIC Capital Management UK LLP (US$35.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RXRX
- ARK Invest 44.75M sh · $184.80M · Q3 2026
- SOFTBANK GROUP CORP. 13.64M sh · $50.05M · Q2 2026
- MIC Capital Management UK LLP 9.64M sh · $35.39M · Q2 2026
- Data Collective IV GP, LLC 5.94M sh · $21.80M · Q2 2026
- DCVC Opportunity Fund II GP, LLC 3.95M sh · $14.50M · Q2 2026
More on IQ EQ FUND MANAGEMENT (IRELAND) Ltd
FAQ
How long has IQ EQ FUND MANAGEMENT (IRELAND) Ltd held RXRX?
IQ EQ FUND MANAGEMENT (IRELAND) Ltd has disclosed RXRX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is IQ EQ FUND MANAGEMENT (IRELAND) Ltd's current position in RXRX?
As of Q3 2026, IQ EQ FUND MANAGEMENT (IRELAND) Ltd holds 2.68M shares of RXRX (RECURSION PHARMACEUTICALS IN), valued at $11.06M, representing 0.68% of its reported portfolio and ranking #48.
Has IQ EQ FUND MANAGEMENT (IRELAND) Ltd been buying or selling RXRX?
In the latest 13F filing (Q3 2026), IQ EQ FUND MANAGEMENT (IRELAND) Ltd increased its position in RXRX. The position peaked in Q3 2026 at 2.68M shares.
Which other funds hold RXRX?
Other major institutional holders of RXRX include ARK Invest, SOFTBANK GROUP CORP., MIC Capital Management UK LLP, among 28 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.